+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Recurrent Glioblastoma Multiforme (GBM) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768020
  • Report
  • April 2019
  • Region: Global
  • 327 pages
  • VPA Research

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eisai Co Ltd
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GW Pharmaceuticals Plc
The global clinical trial report- “2019 Recurrent Glioblastoma Multiforme (GBM) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Recurrent Glioblastoma Multiforme (GBM). It presents in-depth analysis of Recurrent Glioblastoma Multiforme (GBM) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Recurrent Glioblastoma Multiforme (GBM).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Recurrent Glioblastoma Multiforme (GBM) clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Recurrent Glioblastoma Multiforme (GBM)

The research work is prepared through extensive and continuous research on Recurrent Glioblastoma Multiforme (GBM) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Recurrent Glioblastoma Multiforme (GBM) patients are identified
  • The report includes panorama of Recurrent Glioblastoma Multiforme (GBM) clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Recurrent Glioblastoma Multiforme (GBM) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eisai Co Ltd
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GW Pharmaceuticals Plc
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Recurrent Glioblastoma Multiforme (GBM) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Recurrent Glioblastoma Multiforme (GBM) Clinical Trials by Region
2.2.2 Average Enrollment of Recurrent Glioblastoma Multiforme (GBM) Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Recurrent Glioblastoma Multiforme (GBM) Treatment, 2019

3. Region wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials
3.1 Asia Pacific Recurrent Glioblastoma Multiforme (GBM) Clinical Trials by Country
3.2 Europe Recurrent Glioblastoma Multiforme (GBM) Clinical Trials by Country
3.3 North America Recurrent Glioblastoma Multiforme (GBM) Clinical Trials by Country
3.4 Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Clinical Trials by Country
3.5 South and Central America Recurrent Glioblastoma Multiforme (GBM) Clinical Trials by Country

4. Recurrent Glioblastoma Multiforme (GBM) Clinical Trial Trends
4.1 Start Year wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials
4.2 Phase wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials
4.3 Trial Status wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials
4.4 Trial Type wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials

5. Recurrent Glioblastoma Multiforme (GBM) Average Enrollment Trends
5.1 Average Enrollment in Recurrent Glioblastoma Multiforme (GBM) Trials by Year
5.2 Average Enrollment in Recurrent Glioblastoma Multiforme (GBM) Trials by Phase
5.3 Average Enrollment in Recurrent Glioblastoma Multiforme (GBM) Trials by Status
5.4 Average Enrollment in Recurrent Glioblastoma Multiforme (GBM) Trials by Type of Trial

6. Companies Participating in Recurrent Glioblastoma Multiforme (GBM) Clinical Trials
6.1 Recurrent Glioblastoma Multiforme (GBM) Trials by Sponsor Type
6.2 Recurrent Glioblastoma Multiforme (GBM) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Recurrent Glioblastoma Multiforme (GBM) Trials- Phase 1
7.2 Recurrent Glioblastoma Multiforme (GBM) Trials- Phase 2
7.3 Recurrent Glioblastoma Multiforme (GBM) Trials- Phase 3
7.4 Recurrent Glioblastoma Multiforme (GBM) Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Recurrent Glioblastoma Multiforme (GBM) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials and Enrolment
Figure 5: Europe - Country wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials and Enrolment
Figure 7: North America - Country wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials and Enrolment
Figure 9: Recurrent Glioblastoma Multiforme (GBM) Clinical Trials by Phase
Figure 10: Recurrent Glioblastoma Multiforme (GBM) Clinical Trials by Trial Status
Figure 11: Recurrent Glioblastoma Multiforme (GBM) Clinical Trials by Type
Figure 12: Recurrent Glioblastoma Multiforme (GBM) Clinical Trials by Sponsor Type
Figure 13: Recurrent Glioblastoma Multiforme (GBM) Clinical Trials by Leading Sponsors
Figure 14: Recurrent Glioblastoma Multiforme (GBM) Average Enrollment by Phase
Figure 15: Recurrent Glioblastoma Multiforme (GBM) Average Enrollment by Trial Status
Figure 16: Recurrent Glioblastoma Multiforme (GBM) Average Enrollment by Type
Figure 17: Recurrent Glioblastoma Multiforme (GBM)- Average Enrolment by Type of Sponsors
Figure 18: Recurrent Glioblastoma Multiforme (GBM)- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Recurrent Glioblastoma Multiforme (GBM) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials and Enrolment
Table 5: Europe - Country wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials and Enrolment
Table 7: North America - Country wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Recurrent Glioblastoma Multiforme (GBM) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Recurrent Glioblastoma Multiforme (GBM) Average Enrollment by Phase
Table 15: Recurrent Glioblastoma Multiforme (GBM) Average Enrollment by Trial Status
Table 16: Recurrent Glioblastoma Multiforme (GBM) Average Enrollment by Type
Table 17: Recurrent Glioblastoma Multiforme (GBM)- Average Enrolment by Type of Sponsors
Table 18: Recurrent Glioblastoma Multiforme (GBM)- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eisai Co Ltd
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GW Pharmaceuticals Plc
  • Merck & Co Inc
  • Novartis AG
  • NovoCure Ltd
  • Pfizer Inc
Note: Product cover images may vary from those shown
Adroll
adroll